Menu
Recruiting NCT06843707

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

— Observational Lung Cancer Lung Lung Cancer (NSCLC) Metabolomics

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples..
Who it may be relevant to
Registry conditions: Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.

Overview

This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.

Interventions

  • Other Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
    This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the developm

Primary outcome measures

  • Area Under the Curve [Time frame: 3 Years]
Secondary outcome measures (1)
  • Differentially Expressed Metabolites [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • Signing of the informed consent form;
  • Male or female, aged 18-75 years;
  • Patients with lung nodules confirmed by CT examination;
  • Good preoperative pulmonary function cooperation and complete reporting;
  • Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
  • The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.

Exclusion criteria

  • Poor preoperative pulmonary function cooperation or missing reports;
  • Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
  • The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
  • Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
  • Coexisting with other severe functional impairments;
  • Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • the First Affiliated of Guangzhou Medical University — Guangzhou

Identifiers

NCT: NCT06843707 · LungMet · 2025-01-12

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗